DDInter1912 DDInter899
Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Valganciclovir {u} (Compound) resembles {v} (Compound) Penciclovir
Valganciclovir {u} (Compound) resembles {v} (Compound) Acyclovir
Valganciclovir {u} (Compound) binds {v} (Gene) SLC15A1
Valganciclovir {u} (Compound) is included by {v} (Pharmacologic Class) Nucleoside Analog
Valganciclovir {u} (Compound) causes {v} (Side Effect) Anorexia
Valganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Valganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Valganciclovir {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Valganciclovir {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Valganciclovir (Compound) resembles Penciclovir (Compound)
Valganciclovir (Compound) resembles Acyclovir (Compound)
Valganciclovir (Compound) binds SLC15A1 (Gene)
Valganciclovir (Compound) is included by Nucleoside Analog (Pharmacologic Class)
Valganciclovir (Compound) causes Anorexia (Side Effect)
Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Valganciclovir may lead to a major life threatening interaction when taken with Certolizumab pegol
Valganciclovir may lead to a major life threatening interaction when taken with Infliximab